Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7487419 | 0.86 | PDGFRB (0.70) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL7486400 | 0.86 | FGFR2 (0.84) | PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL31060411 | 0.86 | PDGFRA (0.75) | PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL7485861 | 0.86 | EGFR (0.66) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL1496287 | 0.86 | PDGFRB (0.57) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL23528183 | 0.85 | PDGFRA (0.56) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL925876 | 0.85 | PDGFRB (1.00) | PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL29573413 | 0.85 | PDGFRB (1.00) | PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL17117826 | 0.85 | FGFR2 (0.78) | PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL10296327 | 0.85 | PDGFRB (0.56) | PDGFRBPDGFRAFGFR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2017029362-A1 | ASYMMETRIC BISAMIDATION OF MALONIC ESTER DERIVATIVES | SANDOZ AG (CH) | 2017-02-23 | — | — | WO | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20050245570-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | DENINNO MICHAEL P | 2005-11-03 | — | — | US | disclosed |
| EP-1114031-B1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6906082-B2 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-0987251-B1 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | PFIZER PROD INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040092550-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| US-6586448-B1 | Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-6362198-B1 | ANTICHOLESTEROL, ANTILIPEMIC AGENT | PFIZER INC. | 2002-03-26 | — | — | US | disclosed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
| US-6140342-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR; USED TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN OTHER PLASMA LIPID LEVELS, SUCH AS LDL-CHOLESTEROL AND TRIGLYCERIDES | PFIZER INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0987251-A1 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | Pfizer Products Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRB 30/4885PDGFRA 63/4885FGFR2 590/4885 |
| US-20040092550-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | CETP, APOB, NR1H2 | PDGFRB 1074/4885PDGFRA 1689/4885FGFR2 4594/4885 |
| US-20050245570-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | CETP, APOB, HDLBP | PDGFRB 965/4885PDGFRA 1310/4885FGFR2 4683/4885 |
| US-20140155396-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRB 90/4885PDGFRA 182/4885FGFR2 529/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRB 30/4885PDGFRA 63/4885FGFR2 590/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRB 30/4885PDGFRA 63/4885FGFR2 590/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRB 90/4885PDGFRA 182/4885FGFR2 529/4885 |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | TYRO3, MERTK, AXL | PDGFRB 44/4885PDGFRA 111/4885FGFR2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.